Breckenridge Pharmaceutical announced a voluntary nationwide recall on November 16 of one lot of propranolol hydrochloride extended-release capsules, 60 mg, after the company said the capsules may contain pieces of metal. The risk is a laceration of soft tissue in the mouth, esophagus, stomach, or intestine. The company said it was not aware of any adverse health events connected to the recall.

The recall is small by the standards of the pharmaceutical industry. It covers a single lot, one strength, one package size. That narrowness is the reassuring part and the difficult part at the same time. A recall that reaches one lot asks patients to check a detail that few of them keep and fewer can interpret: the lot number printed on a bottle.

What the recall covers

The affected product is propranolol hydrochloride extended-release capsules, USP, 60 mg, in a 100-count bottle. The lot number is PK25110035. The NDC is 51991-817-01. The expiration date on the lot is May 2029. Breckenridge distributed the lot nationwide to wholesalers and pharmacies between October 26 and November 4, 2026, NBC Chicago reported.

The recall is consumer-level, which means the people who may have the product at home are part of the chain. Breckenridge asked patients to stop taking the affected lot immediately and to contact their doctor. Unused product should be returned to the pharmacy where it was obtained. Wholesalers, pharmacies, and retailers were asked to check their inventories and quarantine the lot.

Consumer-level is one of the more demanding recall depths. A wholesale-level recall stops at the distributor, and a retail-level recall stops at the pharmacy shelf. A consumer-level recall reaches the person who already filled the prescription. The company has to rely on the pharmacy to contact patients, and the patient has to recognize that the notice applies to a bottle in the house. That is a longer chain than a warehouse quarantine, and it is the reason the lot number matters so much.

The company set up a recall response line through Qualanex, its recall service provider, at 1-855-736-0807, open Monday through Friday from 9 a.m. to 5 p.m. Eastern time, with an email address at [email protected]. Fox 13 Seattle reported that wholesalers, pharmacies, and retailers were told to check inventories and quarantine affected product. Adverse events can be reported through the FDA's MedWatch program.

The intermediate material behind the recall

Breckenridge's account of the cause is technical and worth reading closely. The company said the affected lot shared intermediate material that is suspected to be the source of metal contamination identified in a separate lot that was not released to market. The product was manufactured by Adare Pharma Solutions.

An intermediate is the material that exists between the active pharmaceutical ingredient and the finished capsule. In a solid oral dose, it can be a blend, a granulation, or a coated particle that is held before encapsulation. Sharing an intermediate across lots is normal. It is how a manufacturer achieves consistency and scale. It is also how a problem in one batch can reach another batch that otherwise looks unrelated.

Metal in a solid dose can come from several places in a plant: worn equipment, a damaged screen, a shared bin, or a handling step that was not cleaned between runs. The recall notice does not identify which of those, if any, is the mechanism here. It names a shared intermediate as the suspected source and leaves the engineering question to the investigation. Adare, the manufacturer, has not issued a public account of the contamination that this article could verify.

The recall notice does not say that the metal was found in the released lot. It says the released lot shared material with a lot where metal contamination was identified, and that the shared material is suspected as the source. That distinction matters. A precautionary recall is built on a plausible route of contamination, not on a confirmed finding in every bottle. The company is narrowing the uncertainty by pulling the lot rather than waiting for a patient to resolve it.

The presence of two companies in the notice is also normal and easy to miss. Breckenridge is the label holder that distributed the product and ran the recall. Adare is the manufacturer. A patient who looks at the bottle sees one name. The supply chain behind that name can include a contract manufacturer, an intermediate supplier, and a distributor, each with its own records. The recall works only if those records connect.

The medicine in the bottle

Propranolol is a beta blocker used for several conditions. The extended-release form is prescribed for hypertension, angina, and migraine prevention, among other uses. It is a long-standing generic, widely prescribed, and generally familiar to pharmacists.

The extended-release design is part of the reason the recall is limited to one lot and one strength. A 60 mg extended-release capsule is not interchangeable with a 60 mg immediate-release tablet. The capsule releases the drug over a day. Splitting or crushing it changes the release profile, which is why patients are told not to open the capsules. A piece of metal in a capsule that is designed to be swallowed whole is a different exposure than a contaminant in a tablet that can be inspected.

The practical advice is not to stop the medication on the strength of a news report. Stopping a beta blocker abruptly can cause a rebound in blood pressure or angina. A patient who has a bottle from the affected lot should call the prescriber or the pharmacy, and the prescriber can decide whether to switch to another lot or another product. A patient who does not know the lot should call the pharmacy, which has the dispensing record.

A lot number is a thin thread for a patient

The recall depends on a number that is printed on the bottle label and, in many cases, on the carton that was thrown away months ago. Patients who use mail-order pharmacies may have a 90-day supply in a single bottle. Patients who transfer prescriptions may have bottles from more than one distributor. The NDC identifies the product and the labeler, but the lot is the unit of the recall.

That is why the pharmacy is the practical starting point. The dispensing record links the patient, the fill date, the NDC, and the lot. A pharmacist can look at the bottle, compare the number, and check the wholesaler's recall notices. The same record lets the pharmacy contact patients directly when a recall is consumer-level, though the notice does not guarantee that every patient will be reached.

Breckenridge's notice asks patients to return unused product to the pharmacy. That is a distribution step, not a disposal instruction. Pharmacies have procedures for recalled stock, and returning the bottle keeps the lot traceable and out of the household.

What a one-lot recall says about the generic supply chain

Recalls at this scale are common in the generic market. A single lot can be withdrawn because of a manufacturing deviation, a packaging error, or a contamination finding. Most never become national news. The ones that do tend to involve a risk that is easy to describe: metal, glass, a wrong tablet, a label mix-up.

The interesting question in this recall is not whether the system worked. It is how much the system can see. Breckenridge traced the suspect material to a shared intermediate and a separate lot that was never released. That is a functioning traceability chain on the manufacturing side. The weakness appears at the other end, where the patient has to connect a bottle in a medicine cabinet to a notice published by a company whose name may not be the one on the prescription.

The FDA's enforcement report will carry the recall classification and the scope. The agency did not issue a separate press release at the time of the company's announcement, which is not unusual for a firm-initiated recall. The company notice and the pharmacy records are the operative documents for a patient.

Recall classifications are assigned after the event, and they describe the probability of harm rather than the size of the recall. A Class I recall covers a reasonable probability of serious harm or death. A Class II recall covers a temporary or medically reversible harm, or a remote probability of serious harm. A Class III recall covers a situation where the product is unlikely to cause harm. The classification will tell a patient how the agency read the metal risk. It will not change the instruction to check the lot.

What to do with a bottle

Check the label for the lot number. If it reads PK25110035, stop taking the capsules and call the prescriber. If the bottle is from a different lot, the recall does not cover it, and the patient should continue the medication as prescribed. If the lot cannot be read or the carton is gone, call the pharmacy and ask it to check the dispensing record.

Do not stop a beta blocker abruptly without medical advice. Do not take a capsule that appears damaged or contains a visible foreign object, regardless of the lot. Report any suspected adverse event to the FDA's MedWatch program and tell the prescriber.

A patient who takes several medications should check the propranolol bottle specifically. Recalls are product-specific, and a notice about one drug says nothing about the others in the cabinet. A patient who takes the immediate-release form of propranolol is not covered by this recall, because the affected product is the extended-release 60 mg capsule. The strength and the release mechanism are part of the identity of the recalled product, not incidental details.

The recall notice is narrow, and most patients on propranolol are not affected. The lot is one of many in a generic market that fills millions of prescriptions. The value of the notice is that it makes the one lot findable, if the patient and the pharmacy take the step to look.

The gap between a recall and a medicine cabinet

A recall is an instruction that travels through a supply chain and ends at a person holding a bottle. The manufacturer can trace an intermediate. The wholesaler can trace a case. The pharmacy can trace a fill. The patient has to trace a label. Each link is routine, and each depends on the one before it.

Breckenridge's recall will be judged by whether the affected lot comes back and whether anyone was hurt by a capsule that should never have been dispensed. The company has said it knows of no injuries so far. The lot number is the thread that runs through the whole story, and it is the one detail a patient can still check.

Primary sources

  1. Breckenridge Pharmaceutical recall notice, as reported by NBC Chicago, for the product description, lot number, NDC, distribution dates, and consumer instructions.
  2. Fox 13 Seattle, for the recall's risk language, the Qualanex contact details, and the company's statement that it was not aware of adverse events.
  3. USA Today, for the nationwide scope and the November 16 announcement date.
  4. FDA MedWatch, for adverse event reporting.